Afatinib Shows Potential in NRG1-Positive Gastrointestinal Cancers

Kristi Rosa
Published: Wednesday, Jul 31, 2019
Benjamin Weinberg, MD

Benjamin Weinberg, MD

New case reports show that afatinib (Gilotrif) may be a potential treatment option for patients with rare NRG1 fusion–positive gastrointestinal (GI) cancers, said Benjamin Weinberg, MD, especially if given earlier on in the treatment course.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication